The safety and tolerability profile of bilastine for chronic urticaria in children
Abstract Background Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, alw...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-10-01
|
| Series: | Clinical and Translational Allergy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13601-019-0294-3 |
| _version_ | 1818584142467563520 |
|---|---|
| author | Nikolaos G. Papadopoulos Torsten Zuberbier |
| author_facet | Nikolaos G. Papadopoulos Torsten Zuberbier |
| author_sort | Nikolaos G. Papadopoulos |
| collection | DOAJ |
| description | Abstract Background Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition. Therefore, the management of chronic urticaria must point to a complete control of symptoms, taking into account tolerability and the patient quality of life. Review of literature The recently revised version of EAACI/GA2LEN/EDF/WAO guideline on the management of urticaria, in addition to recommending the use of second-generation H1 antihistamines as the treatment of choice, gives particular attention to their use in the paediatric population. Bilastine has been studied in children; at the dose of 10 mg/once daily, it is licenced for the symptomatic relief of urticaria in children ≥ 6 to 11 years, in the European Union, in appropriate formulation, as oral solution or orodispersible tablet. Conclusions In line with the recent guideline recommendation for the use of second generation H1 antihistamines in children we have reviewed the safety and tolerability profile of bilastine in children with chronic urticaria. |
| first_indexed | 2024-12-16T08:16:28Z |
| format | Article |
| id | doaj.art-17ba4d94b3c347eb8b9e07202d9c80f8 |
| institution | Directory Open Access Journal |
| issn | 2045-7022 |
| language | English |
| last_indexed | 2024-12-16T08:16:28Z |
| publishDate | 2019-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Allergy |
| spelling | doaj.art-17ba4d94b3c347eb8b9e07202d9c80f82022-12-21T22:38:13ZengWileyClinical and Translational Allergy2045-70222019-10-01911710.1186/s13601-019-0294-3The safety and tolerability profile of bilastine for chronic urticaria in childrenNikolaos G. Papadopoulos0Torsten Zuberbier1Allergy Department, 2nd Pediatric Clinic, University of AthensDepartment of Dermatology, Venerology and Allergy, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, Berlin Institute of HealthAbstract Background Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition. Therefore, the management of chronic urticaria must point to a complete control of symptoms, taking into account tolerability and the patient quality of life. Review of literature The recently revised version of EAACI/GA2LEN/EDF/WAO guideline on the management of urticaria, in addition to recommending the use of second-generation H1 antihistamines as the treatment of choice, gives particular attention to their use in the paediatric population. Bilastine has been studied in children; at the dose of 10 mg/once daily, it is licenced for the symptomatic relief of urticaria in children ≥ 6 to 11 years, in the European Union, in appropriate formulation, as oral solution or orodispersible tablet. Conclusions In line with the recent guideline recommendation for the use of second generation H1 antihistamines in children we have reviewed the safety and tolerability profile of bilastine in children with chronic urticaria.http://link.springer.com/article/10.1186/s13601-019-0294-3Chronic urticariaSecond generation-antihistamineBilastineChildren |
| spellingShingle | Nikolaos G. Papadopoulos Torsten Zuberbier The safety and tolerability profile of bilastine for chronic urticaria in children Clinical and Translational Allergy Chronic urticaria Second generation-antihistamine Bilastine Children |
| title | The safety and tolerability profile of bilastine for chronic urticaria in children |
| title_full | The safety and tolerability profile of bilastine for chronic urticaria in children |
| title_fullStr | The safety and tolerability profile of bilastine for chronic urticaria in children |
| title_full_unstemmed | The safety and tolerability profile of bilastine for chronic urticaria in children |
| title_short | The safety and tolerability profile of bilastine for chronic urticaria in children |
| title_sort | safety and tolerability profile of bilastine for chronic urticaria in children |
| topic | Chronic urticaria Second generation-antihistamine Bilastine Children |
| url | http://link.springer.com/article/10.1186/s13601-019-0294-3 |
| work_keys_str_mv | AT nikolaosgpapadopoulos thesafetyandtolerabilityprofileofbilastineforchronicurticariainchildren AT torstenzuberbier thesafetyandtolerabilityprofileofbilastineforchronicurticariainchildren AT nikolaosgpapadopoulos safetyandtolerabilityprofileofbilastineforchronicurticariainchildren AT torstenzuberbier safetyandtolerabilityprofileofbilastineforchronicurticariainchildren |